Diabetes Obes Metab 2022; doi:10.1111/dom.14670
In this study of adults with T2D and established CV disease, the proportion of patients at high steatosis risk decreased slightly in patients treated with empagliflozin compared with patients treated with placebo. Fibrosis risk was not reduced.
People with T2D often have NAFLD. This post-hoc study by Kahl et al evaluated the effects of empagliflozin on risk for NAFLD-related steatosis and fibrosis, as well as the relationship between risk categories and cardiorenal outcomes in EMPA-REG OUTCOME.